Hopkinton-based Caliper Life Sciences Inc. saw its net loss for the fourth quarter balloon to $8.9 million from the $1.5 million loss the firm reported during the same period a year earlier.
Caliper, which is a provider of instruments and services for pre-clinical drug research, acquired Xenogen Corp. in August for about $80 million. Xenogen’s operations were consolidated within 4 1/2 months and $11 million in annual cost savings were achieved, according to Caliper.
The full year results for Caliper also included a widening net loss, which increased from $14.5 million in 2005 to $28.9 million in 2006.
Moving forward, the company said its revenue outlook for the first quarter of 2007 is $28 to $32 million (growth of 26% to 43%) and its revenue outlook for the full year is $137 to $143 million (growth of 27% to 33%).
